BONZUN: Merger with L2S a favorable reconfiguration for Bonzun’s shareholders
Bonzun has agreed to sell all shares in its subsidiary Bonzun Evolve to CBT-based sleep therapy company Learning to Sleep
BONZUN
Bonzun is active in the healthcare sector. The company is focused on delivering technical services and solutions in health. The services include fertility treatments and stress programs, which are delivered in digital form to various corporate customers and private individuals. In addition, the company offers a digital program that supports self-development and stress management through behavioral therapy.
RESEARCH
Bonzun has agreed to sell all shares in its subsidiary Bonzun Evolve to CBT-based sleep therapy company Learning to Sleep
While still modest in absolute terms, the Q1 sales growth and deals year-to-date signed affirm the growth story we see
On the back of the framework agreement with the Swedish Security Council (TRR) for Bonzun’s digital CBT service Evolve signed
After a comprehensive adjustment of business focus, balance sheet, costs and valuation in 2022, along with a recent restocking of
We re-initiate coverage on digital therapeutics (DTx) company Bonzun that offers evidence-based patient support for fertility treatments (IVF) and a
The Q2’22 report showed some continued progress for Bonzun’s stress management service, Bonzun Evolve, with 450 new licenses from KTH
BONZUN The Q1’22 report showed some progress for Bonzun’s stress management service, Bonzun evolve, with an increased number of licenses
Med en nystart för försäljningen av Bonzun evolve (tidigare Stressprogrammet) med 141% tillväxt 2021, 25% ökning i MRR för Bonzun
Efter höstens utdragna nedgång i aktiekursen annonserade Bonzun till slut en fullt garanterad nyemission på 14 MSEK. Med begränsat finansiellt
Efter Papillys omvända förvärv av Bonzun är fokus inställt på att på digital väg stötta de kvinnor som genomgår psykiskt
Den starka tillväxten (om än från mycket låga nivåer) i Bonzuns första rapport som noterat bolag skänker trovärdighet åt ledningens
For new research on growth stocks, sign up to our newsletter